Maze Therapeutics (MAZE) EBT (2024 - 2026)

Maze Therapeutics has reported EBT for 3 years, with the latest figure at -$19.6 million in Q1 2026.

• Quarterly EBT rose 40.23% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.9 million (down 322.04% YoY) and the FY2025 annual result came in at -$131.1 million, down 345.53% from the prior year.
• EBT improved to -$19.6 million in Q1 2026 per MAZE's latest filing, from -$34.6 million in the prior quarter.
• Over five years, EBT peaked at $140.8 million in Q2 2024 and troughed at -$34.6 million in Q4 2025.
• A 3-year average of -$10.3 million and a median of -$29.9 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2025 and 2026: EBT tumbled 123.92% in 2025, then surged 40.23% in 2026.
• Over 3 years, EBT stood at -$29.9 million in 2024, then slipped by 15.79% to -$34.6 million in 2025, then jumped by 43.31% to -$19.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$19.6 million, -$34.6 million, and -$30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.